IBDEI0HQ ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8271,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,8272,0)
 ;;=238.4^^35^482^109
 ;;^UTILITY(U,$J,358.3,8272,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8272,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,8272,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,8272,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,8273,0)
 ;;=V58.61^^35^482^126
 ;;^UTILITY(U,$J,358.3,8273,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8273,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,8273,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,8273,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,8274,0)
 ;;=282.49^^35^482^117
 ;;^UTILITY(U,$J,358.3,8274,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8274,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,8274,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,8274,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,8275,0)
 ;;=289.89^^35^482^15
 ;;^UTILITY(U,$J,358.3,8275,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8275,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,8275,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,8275,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,8276,0)
 ;;=238.79^^35^482^88
 ;;^UTILITY(U,$J,358.3,8276,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8276,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,8276,1,5,0)
 ;;=5^Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,8276,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,8277,0)
 ;;=287.30^^35^482^110
 ;;^UTILITY(U,$J,358.3,8277,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8277,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,8277,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,8277,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,8278,0)
 ;;=288.09^^35^482^8
 ;;^UTILITY(U,$J,358.3,8278,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8278,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,8278,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,8278,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,8279,0)
 ;;=V10.21^^35^482^61
 ;;^UTILITY(U,$J,358.3,8279,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8279,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,8279,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,8279,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,8280,0)
 ;;=284.2^^35^482^106
 ;;^UTILITY(U,$J,358.3,8280,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8280,1,4,0)
 ;;=4^284.2
 ;;^UTILITY(U,$J,358.3,8280,1,5,0)
 ;;=5^Myelophthisic Anemia
 ;;^UTILITY(U,$J,358.3,8280,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,8281,0)
 ;;=202.40^^35^482^76
 ;;^UTILITY(U,$J,358.3,8281,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8281,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,8281,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,8281,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,8282,0)
 ;;=287.49^^35^482^118
 ;;^UTILITY(U,$J,358.3,8282,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8282,1,4,0)
 ;;=4^287.49
 ;;^UTILITY(U,$J,358.3,8282,1,5,0)
 ;;=5^Thrombocytopenia,Drug Induced
 ;;^UTILITY(U,$J,358.3,8282,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,8283,0)
 ;;=180.9^^35^482^29
 ;;^UTILITY(U,$J,358.3,8283,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8283,1,4,0)
 ;;=4^180.9
 ;;^UTILITY(U,$J,358.3,8283,1,5,0)
 ;;=5^Ca Cervix
 ;;^UTILITY(U,$J,358.3,8283,2)
 ;;=^267214
 ;;^UTILITY(U,$J,358.3,8284,0)
 ;;=203.02^^35^482^104
 ;;^UTILITY(U,$J,358.3,8284,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8284,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,8284,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,8284,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,8285,0)
 ;;=204.02^^35^482^2
 ;;^UTILITY(U,$J,358.3,8285,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8285,1,4,0)
 ;;=4^204.02
 ;;
 ;;$END ROU IBDEI0HQ
